AlphaCentric Advisors’s Cymabay Therapeutics CBAY Stock Holding History

AlphaCentric Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$236K	–	252
2023 Q4	$236K	Sell	10,000 -5,000	-33%	-$89K	0.16%	101
2023 Q3	$224K	Hold	15,000	–	–	0.13%	133
2023 Q2	$164K	Buy	+15,000	New	+$140K	0.09%	159

Other funds holding CBAY

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AlphaCentric Advisors's CBAY Position: Q1 2024 in Review

AlphaCentric Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 10,000 shares — an estimated $236K sold.

AlphaCentric Advisors first reported a position in CBAY in Q2 2023 and held it in 3 quarters. The position peaked at $236K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

AlphaCentric Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
AlphaCentric Advisors sold 10,000 Cymabay Therapeutics shares in Q1 2024, an estimated $236K.
AlphaCentric Advisors first reported a position in Cymabay Therapeutics in Q2 2023 and held it in 3 quarters.
AlphaCentric Advisors's Cymabay Therapeutics position peaked at $236K in Q4 2023.
1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on AlphaCentric Advisors's 13F filing for Q1 2024, filed 24 Apr 2024.